Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Full-Year 2016 Financial Results
SOLANA BEACH, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial results for the fourth quarter and full year ended December 31,
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Year End 2015 Financial Results
SOLANA BEACH, Calif., March 04, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the fourth quarter and full year 2015 on Thursday,
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results
SOLANA BEACH, Calif. , July 30, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2014 on Wednesday, August 13,
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2015 Financial Results
SOLANA BEACH, Calif. , July 30, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2015 on Thursday, August 13,
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2016 Financial Results
SOLANA BEACH, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter 2016 on Monday, August 15, 2016,
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2013 Financial Results
SAN DIEGO , Nov. 5, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Third Quarter of 2013 on Wednesday, November 13, 2013 , after
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results
SOLANA BEACH, Calif. , Nov. 6, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Third Quarter of 2014 on Thursday, November 13,
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2015 Financial Results
SOLANA BEACH, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the third quarter of 2015 on Thursday, November 12,
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2016 Financial Results
SOLANA BEACH, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the third quarter 2016 on Wednesday, November 9, 2016,
View HTML
Toggle Summary Evoke Pharma Secures $4.5 Million Loan Facility With Square 1 Bank
SOLANA BEACH, Calif. , May 28, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has secured a $4.5 million term loan agreement with Square 1 Bank (Nasdaq:SQBK).
View HTML